Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Taysha Gene Therapies, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 39 | 63 | +24 |
| Shares | 13.7M | 130.0M | +116.3M (+848.4%) |
| Value | $9.05M | $410.6M | +$401.6M (+4,435.1%) |
New holders (35)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (11)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Nantahala Capital Management, LLC | 1,251,139 | $827.0K |
| Laurion Capital Management LP | 1,171,832 | $774.6K |
| Millennium Management LLC | 614,938 | $406.5K |
| Carlson Capital L P | 484,000 | $319.9K |
| Acadian Asset Management LLC | 70,798 | $46.0K |
| Sargent Investment Group, LLC | 25,634 | $16.9K |
| Gsa Capital Partners LLP | 18,077 | $12.0K |
| Tower Research Capital LLC (TRC) | 14,435 | $9.54K |
| Engineers Gate Manager LP | 13,650 | $9.02K |
| Citadel Advisors LLC | 11,293 | $7.46K |
| Camelot Portfolios, LLC | 11,000 | $7.27K |